person · Reporting owner

MITCHELL DEAN J

Disclosed activity across 6 companies

Tapewire entity: 17741
SEC CIK: 0001199297

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BRISTOL MYERS SQUIBB CO(BMY) · Entity 1662	President, U.S. Primary Care	September 10, 2003	September 12, 2003
PRECIGEN, INC.PGEN · Entity 4356	Director	March 14, 2024	March 18, 2024
Praxis Precision Medicines, Inc.PRAX · Entity 3538	Director	June 10, 2026	June 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BRISTOL MYERS SQUIBB CO

Report date September 10, 2003 · Filed September 12, 2003

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.10 par valueSEC Table I · non-derivative	Direct	60,000	Reported balance After 2003-09-10 transaction · row 1 1 source row Row 1 · 2003-09-10 · Grant · Acquired 10,000 · Balance 60,000 F1: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.
Common Stock, $0.10 par valueSEC Table I · non-derivative	IndirectBy BMY Savings & Investment Program	567.86	Reported balance Holding disclosure · report date 2003-09-10 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 567.86 F2: Based on a plan statement as of the end of the most recent fiscal quarter.

Filing footnotes · ownership attribution and instrument terms

F1: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.

F2: Based on a plan statement as of the end of the most recent fiscal quarter.

PRECIGEN, INC.

Report date March 14, 2024 · Filed March 18, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	503,183	Reported balance After 2024-03-14 transaction · row 1 1 source row Row 1 · 2024-03-14 · Grant · Acquired 39,510 · Balance 503,183 F1: The shares were issued to the reporting person in lieu of an annual retainer of $56,499.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	87,412	Reported balance After 2024-03-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-03-14 · Grant · Acquired 87,412 · Balance 87,412 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3: The RSUs vest in full on March 14, 2025.
Option to Purchase Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.43 · Expires 2034-03-14	Direct	101,626	Reported balance After 2024-03-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-03-14 · Grant · Acquired 101,626 · Balance 101,626

Filing footnotes · ownership attribution and instrument terms

F1: The shares were issued to the reporting person in lieu of an annual retainer of $56,499.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

F3: The RSUs vest in full on March 14, 2025.

Praxis Precision Medicines, Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,622	Reported balance After 2026-06-10 transaction · row 1 1 source row Row 1 · 2026-06-10 · Grant · Acquired 1,371 · Balance 18,622 F1: Mr. Mitchell was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.66 · Expires 2036-06-10	Direct	648	Reported balance After 2026-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-10 · Grant · Acquired 648 · Balance 648 F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Mr. Mitchell was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ImmunoGen, Inc.

Report date February 12, 2024 · Filed February 12, 2024

Section 16 reporting ended · disclosed 2024-02-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-02-12 transaction · row 1 1 source row Row 1 · 2024-02-12 · Disposition to issuer · Disposed 103,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-02-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-02-12 · Disposition to issuer · Disposed 13,090 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
Deferred Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-02-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-02-12 · Disposition to issuer · Disposed 142,667 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.10 · Expires 2024-11-11	Direct	Reported balance After 2024-02-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.07 · Expires 2025-11-10	Direct	Reported balance After 2024-02-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.21 · Expires 2028-06-20	Direct	Reported balance After 2024-02-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-02-12 · Disposition to issuer · Disposed 18,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2031-06-16	Direct	Reported balance After 2024-02-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2032-06-15	Direct	Reported balance After 2024-02-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.72 · Expires 2033-06-14	Direct	Reported balance After 2024-02-12 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-02-12 · Disposition to issuer · Disposed 19,597 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").

F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

Kinnate Biopharma Inc.

Report date April 03, 2024 · Filed April 05, 2024

Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.63 · Expires 2030-08-18	Direct	Reported balance After 2024-04-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-04-03 · Disposition to issuer · Disposed 121,503 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.46 · Expires 2031-06-11	Direct	Reported balance After 2024-04-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-04-03 · Disposition to issuer · Disposed 20,250 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2032-06-13	Direct	Reported balance After 2024-04-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-04-03 · Disposition to issuer · Disposed 20,250 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.48 · Expires 2033-06-12	Direct	Reported balance After 2024-04-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-04-03 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.

Filing footnotes · ownership attribution and instrument terms

F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.

Theravance Biopharma, Inc.

Report date September 23, 2026 · Filed September 25, 2026

Section 16 reporting ended · disclosed 2026-09-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Ending reported balance After 2026-09-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-23 · Disposition to issuer · Disposed 91,204 · Balance 6,009 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Row 2 · 2026-09-23 · Disposition to issuer · Disposed 6,009 · Balance 0 F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.43 · Expires 2028-04-30	Direct	Reported balance After 2026-09-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.85 · Expires 2029-04-29	Direct	Reported balance After 2026-09-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.14 · Expires 2030-04-27	Direct	Reported balance After 2026-09-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.35 · Expires 2031-04-26	Direct	Reported balance After 2026-09-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.15 · Expires 2032-04-25	Direct	Reported balance After 2026-09-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-09-23 · Disposition to issuer · Disposed 28,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.95 · Expires 2033-05-01	Direct	Reported balance After 2026-09-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-09-23 · Disposition to issuer · Disposed 22,044 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.49 · Expires 2034-05-07	Direct	Reported balance After 2026-09-23 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-09-23 · Disposition to issuer · Disposed 23,576 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.39 · Expires 2035-05-18	Direct	Reported balance After 2026-09-23 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-09-23 · Disposition to issuer · Disposed 24,258 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.64 · Expires 2036-06-11	Direct	Reported balance After 2026-09-23 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-09-23 · Disposition to issuer · Disposed 13,398 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

Filing footnotes · ownership attribution and instrument terms

F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.

F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 03, 2021 Filed Mar 5, 2021 21:58 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionOption to Purchase Common Stock (Right to Buy) · Derivative	2,968	$0.00 Strike: $5.69	$0.00	Disclosure SEC source: 0001123292-21-000414 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,968 shares Expires 2021-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was immediately exercisable. Read SEC document
March 03, 2021 Filed Mar 5, 2021 21:58 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	2,968	$5.69	$16,887.92	Disclosure SEC source: 0001123292-21-000414 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 31, 2020 Filed Jan 4, 2021 10:45 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	2,093	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-21-000025 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,108 Underlying: Common Stock · 2,093 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
September 30, 2020 Filed Oct 1, 2020 14:38 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	3,750	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-20-010029 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,015 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 30, 2020 Filed Jul 2, 2020 08:35 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	2,934	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-20-007816 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,265 Underlying: Common Stock · 2,934 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 19, 2020 Filed Jun 23, 2020 20:57 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionOption to Purchase Common Stock (Right to Buy) · Derivative	2,968	$0.00 Strike: $3.17	$0.00	Disclosure SEC source: 0001123292-20-000920 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,968 shares Expires 2020-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was immediately exercisable. Read SEC document
June 19, 2020 Filed Jun 23, 2020 20:57 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	2,968	$3.17	$9,408.56	Disclosure SEC source: 0001123292-20-000920 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 17, 2020 Filed Jun 18, 2020 16:06 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantStock Option (right to buy) · Derivative	50,000	$4.56 Strike: $4.56	$228,000.00	Disclosure SEC source: 0001179110-20-007528 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-17 F4 · derivative.exercise_date: Exercisable as to 12,500 shares on each of 9/1/20, 12/1/20, 3/1/21 and 6/1/21, contingent upon the individual remaining a director as of each vesting date. Read SEC document
June 17, 2020 Filed Jun 18, 2020 16:06 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	17,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-20-007528 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,331 Underlying: Common Stock · 17,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on each of 9/1/20, 12/1/20, 3/1/21 and 6/1/21, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
April 28, 2020 Filed Apr 30, 2020 22:57 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantShare Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $30.14	$0.00	Disclosure SEC source: 0001179110-20-005301 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2030-04-27 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document
April 28, 2020 Filed Apr 30, 2020 22:57 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantOrdinary Shares	6,635	$0.00	$0.00	Disclosure SEC source: 0001179110-20-005301 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,206 Read SEC document
March 31, 2020 Filed Apr 2, 2020 07:51 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	3,958	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-20-004405 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,331 Underlying: Common Stock · 3,958 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
March 13, 2020 Filed Mar 17, 2020 22:33 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	96,324	$0.00 Strike: $2.01	$0.00	Disclosure SEC source: 0001123292-20-000570 · edgar.xml · derivative · entry 3 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,324 Underlying: Common Stock · 96,324 shares Expires 2030-03-13 Read SEC document
March 13, 2020 Filed Mar 17, 2020 22:33 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantRestricted Stock Units · Derivative	62,189	$0.00	$0.00	Disclosure SEC source: 0001123292-20-000570 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,189 Underlying: Common Stock · 62,189 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Precigen, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in full on March 13, 2021. F3 · derivative.expiration_date: The restricted stock units vest in full on March 13, 2021. Read SEC document
March 13, 2020 Filed Mar 17, 2020 22:33 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantCommon Stock	28,109	$2.01	$56,499.09	Disclosure SEC source: 0001123292-20-000570 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,473 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $56,500. Read SEC document
March 08, 2020 Filed Mar 10, 2020 20:17 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	24,703	$0.00	$0.00	Disclosure SEC source: 0001123292-20-000535 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on March 8, 2020. F2 · derivative.expiration_date: The restricted stock units vested in full on March 8, 2020. Read SEC document
March 08, 2020 Filed Mar 10, 2020 20:17 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	24,703	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-20-000535 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document
December 31, 2019 Filed Jan 2, 2020 09:27 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	2,641	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-20-000001 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,373 Underlying: Common Stock · 2,641 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
September 30, 2019 Filed Oct 2, 2019 11:59 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	5,578	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-19-052439 · a4.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,732 Underlying: Common Stock · 5,578 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 30, 2019 Filed Jul 1, 2019 09:27 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	6,221	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-19-008224 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,154 Underlying: Common Stock · 6,221 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 20, 2019 Filed Jun 24, 2019 10:24 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantStock Option (right to buy) · Derivative	18,000	$2.10 Strike: $2.10	$37,800.00	Disclosure SEC source: 0001179110-19-008040 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2029-06-20 F4 · derivative.exercise_date: Exercisable as to 4,500 shares on 9/1/19, 12/1/19, 3/1/20 and 6/1/20, contingent upon the individual remaining a director as of each vesting date. Read SEC document
June 20, 2019 Filed Jun 24, 2019 10:24 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	4,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-19-008040 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,933 Underlying: Common Stock · 4,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on 9/1/19, 12/1/19, 3/1/20 and 6/1/20, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
April 30, 2019 Filed May 2, 2019 22:23 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantShare Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $23.85	$0.00	Disclosure SEC source: 0001179110-19-005461 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2029-04-29 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document
April 30, 2019 Filed May 2, 2019 22:23 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantOrdinary Shares	8,385	$0.00	$0.00	Disclosure SEC source: 0001179110-19-005461 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,571 Read SEC document
March 31, 2019 Filed Apr 1, 2019 11:32 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	4,981	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-19-004395 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,933 Underlying: Common Stock · 4,981 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
March 23, 2019 Filed Mar 26, 2019 21:51 UTC	PRECIGEN, INC. XON · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	7,911	$0.00	$0.00	Disclosure SEC source: 0001123292-19-000576 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,911 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on March 23, 2019. F2 · derivative.expiration_date: The restricted stock units vested in full on March 23, 2019. Read SEC document
March 23, 2019 Filed Mar 26, 2019 21:51 UTC	PRECIGEN, INC. XON · Entity 4356	Exercise / conversionCommon Stock	7,911	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-19-000576 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document
March 12, 2019 Filed Mar 12, 2019 23:11 UTC	PRECIGEN, INC. XON · Entity 4356	Exercise / conversionOption to Purchase Common Stock (Right to Buy) · Derivative	8,906	$0.00 Strike: $3.17	$0.00	Disclosure SEC source: 0001123292-19-000469 · edgar.xml · derivative · entry 5 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,906 shares Expires 2019-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was immediately exercisable. Read SEC document
March 12, 2019 Filed Mar 12, 2019 23:11 UTC	PRECIGEN, INC. XON · Entity 4356	Exercise / conversionCommon Stock	8,906	$3.17	$28,232.02	Disclosure SEC source: 0001123292-19-000469 · edgar.xml · nonDerivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 08, 2019 Filed Mar 12, 2019 23:11 UTC	PRECIGEN, INC. XON · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	42,450	$0.00 Strike: $5.06	$0.00	Disclosure SEC source: 0001123292-19-000469 · edgar.xml · derivative · entry 4 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,450 Underlying: Common Stock · 42,450 shares Expires 2029-03-08 Read SEC document
March 08, 2019 Filed Mar 12, 2019 23:11 UTC	PRECIGEN, INC. XON · Entity 4356	GrantRestricted Stock Units · Derivative	24,703	$0.00	$0.00	Disclosure SEC source: 0001123292-19-000469 · edgar.xml · derivative · entry 3 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,614 Underlying: Common Stock · 24,703 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units vest in full one year from the grant date. F3 · derivative.expiration_date: The restricted stock units vest in full one year from the grant date. Read SEC document
March 08, 2019 Filed Mar 12, 2019 23:11 UTC	PRECIGEN, INC. XON · Entity 4356	GrantCommon Stock	11,166	$5.06	$56,499.96	Disclosure SEC source: 0001123292-19-000469 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,844 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $56,500. Read SEC document
December 31, 2018 Filed Jan 2, 2019 14:37 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	2,812	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-19-000025 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,952 Underlying: Common Stock · 2,812 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
September 30, 2018 Filed Oct 1, 2018 15:15 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	1,425	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-18-011757 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,140 Underlying: Common Stock · 1,425 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 30, 2018 Filed Jul 2, 2018 11:00 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	1,387	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-18-009168 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,715 Underlying: Common Stock · 1,387 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 20, 2018 Filed Jun 22, 2018 14:17 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantStock option (right to buy) · Derivative	18,000	$11.21 Strike: $11.21	$201,780.00	Disclosure SEC source: 0001179110-18-008936 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-20 F4 · derivative.exercise_date: Exercisable as to 4,500 shares on 9/1/18, 12/1/18, 3/1/19 and 6/1/19, contingent upon the individual remaining a director as of each vesting date. Read SEC document
June 20, 2018 Filed Jun 22, 2018 14:17 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	4,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-18-008936 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,328 Underlying: Common Stock · 4,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on 9/1/18, 12/1/18, 3/1/19 and 6/1/19, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
May 01, 2018 Filed May 3, 2018 22:15 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantShare Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $24.43	$0.00	Disclosure SEC source: 0001179110-18-006191 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document
May 01, 2018 Filed May 3, 2018 22:15 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantOrdinary Shares	8,186	$0.00	$0.00	Disclosure SEC source: 0001179110-18-006191 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,186 Read SEC document
March 31, 2018 Filed Apr 2, 2018 10:53 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	1,283	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-18-004959 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,328 Underlying: Common Stock · 1,283 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
March 23, 2018 Filed Mar 29, 2018 21:56 UTC	PRECIGEN, INC. XON · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	14,246	$0.00 Strike: $15.80	$0.00	Disclosure SEC source: 0001123292-18-000599 · edgar.xml · derivative · entry 3 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,246 Underlying: Common Stock · 14,246 shares Expires 2028-03-23 Read SEC document
March 23, 2018 Filed Mar 29, 2018 21:56 UTC	PRECIGEN, INC. XON · Entity 4356	GrantRestricted Stock Units · Derivative	7,911	$0.00	$0.00	Disclosure SEC source: 0001123292-18-000599 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,911 Underlying: Common Stock · 7,911 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units vest in full one year from the grant date. F3 · derivative.expiration_date: The restricted stock units vest in full one year from the grant date. Read SEC document
March 23, 2018 Filed Mar 29, 2018 21:56 UTC	PRECIGEN, INC. XON · Entity 4356	GrantCommon Stock	3,575	$15.80	$56,485.00	Disclosure SEC source: 0001123292-18-000599 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,678 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $56,500. Read SEC document
December 31, 2017 Filed Jan 3, 2018 13:19 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	1,868	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-18-000217 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,045 Underlying: Common Stock · 1,868 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
September 30, 2017 Filed Oct 3, 2017 08:41 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	1,535	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-17-012870 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,177 Underlying: Common Stock · 1,535 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
August 11, 2017 Filed Aug 11, 2017 17:03 UTC	PRECIGEN, INC. XON · Entity 4356	PurchaseCommon Stock	5,000	$18.33	$91,639.50	Disclosure SEC source: 0001225385-17-000094 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,103 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.24 to $18.37, inclusive. The reporting person undertakes to provide to Intrexon Corporation ("Intrexon"), any security holder of Intrexon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
June 30, 2017 Filed Jul 3, 2017 08:13 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	1,652	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-17-009859 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,642 Underlying: Common Stock · 1,652 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 13, 2017 Filed Jun 15, 2017 09:59 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantStock option (right to buy) · Derivative	10,000	$4.64 Strike: $4.64	$46,400.00	Disclosure SEC source: 0001179110-17-009090 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-13 F4 · derivative.exercise_date: Exercisable as to 2,500 shares on 9/1/17, 12/1/17, 3/1/18 and 6/1/18, contingent upon the individual remaining a director as of each vesting date. Read SEC document
June 13, 2017 Filed Jun 15, 2017 09:59 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	3,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-17-009090 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,990 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on 9/1/17, 12/1/17, 3/1/18 and 6/1/18, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
May 17, 2017 Filed May 18, 2017 22:03 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantOrdinary Shares	6,000	$0.00	$0.00	Disclosure SEC source: 0001179110-17-007541 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.